37793-53-6 Usage
Description
N10-(TRIFLUOROACETYL)PTEROIC ACID is a white solid derivative of Pteroic acid, which is utilized in the synthesis of target ligands such as Folic acid. N10-(TRIFLUOROACETYL)PTEROIC ACID plays a significant role in the development of chemotherapeutic agents that can be specifically delivered to cancer cells, making it a valuable asset in the field of cancer research and treatment.
Uses
Used in Pharmaceutical Industry:
N10-(TRIFLUOROACETYL)PTEROIC ACID is used as a reagent for the synthesis of target ligands like Folic acid, which is crucial for the development of chemotherapeutic agents. The application reason is that these ligands can specifically target and deliver chemotherapeutic agents to cancer cells, enhancing the effectiveness of cancer treatment and reducing side effects on healthy cells.
Used in Cancer Research:
In the field of cancer research, N10-(TRIFLUOROACETYL)PTEROIC ACID is used as a key component in the creation of targeted therapies. The application reason is its ability to facilitate the synthesis of ligands that can selectively bind to cancer cells, allowing for more precise and effective treatment strategies.
Used in Drug Development:
N10-(TRIFLUOROACETYL)PTEROIC ACID is also used in drug development as a starting material for the synthesis of novel compounds with potential anticancer properties. The application reason is its unique chemical structure, which can be modified and optimized to create new drugs that can target specific cancer cell pathways or mechanisms.
Overall, N10-(TRIFLUOROACETYL)PTEROIC ACID is a versatile compound with significant applications in the pharmaceutical industry, cancer research, and drug development, primarily due to its role in the synthesis of target ligands for cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 37793-53-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,7,9 and 3 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 37793-53:
(7*3)+(6*7)+(5*7)+(4*9)+(3*3)+(2*5)+(1*3)=156
156 % 10 = 6
So 37793-53-6 is a valid CAS Registry Number.
InChI:InChI=1/C16H11F3N6O4/c17-16(18,19)14(29)25(9-3-1-7(2-4-9)13(27)28)6-8-5-21-11-10(22-8)12(26)24-15(20)23-11/h1-5H,6H2,(H,27,28)(H3,20,21,23,24,26)
37793-53-6Relevant articles and documents
Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope
Yamaguchi, Aiko,Anami, Yasuaki,Ha, Summer Y.Y.,Roeder, Travis J.,Xiong, Wei,Lee, Jangsoon,Ueno, Naoto T.,Zhang, Ningyan,An, Zhiqiang,Tsuchikama, Kyoji
, (2021)
Antibody-drug conjugates (ADCs) hold great therapeutic promise for cancer indications; however, treating tumors with intratumor heterogeneity remains challenging. We hypothesized that ADCs that can simultaneously target two different cancer antigens could
Synthesis and anti-cancer evaluation of folic acid-peptide- paclitaxel conjugates for addressing drug resistance
Dai, Yuxuan,Cai, Xingguang,Bi, Xinzhou,Liu, Chunxia,Yue, Na,Zhu, Ying,Zhou, Jiaqi,Fu, Mian,Huang, Wenlong,Qian, Hai
, p. 104 - 115 (2019)
The drug resistance and the poor water solubility are major limitations of paclitaxel (PTX) of based chemotherapy. To conquer the two problems, targeting folate (FA) receptor PTX-lytic peptides conjugates were synthesized and evaluated. Compared with PTX, FA-P3-PTX and FA-P7-PTX displayed significantly enhanced cell toxicity in many cancer cells, particularly drug resistant cancer cells MCF-7/PTX. FA-P7-PTX possessed stronger effect on cell toxicity (IC50 = 2.92 ± 0.2 μM), membrane disrupting activity and pro-apoptosis in MCF-7/PTX cells than FA-P3-PTX. Further investigation displayed that the anti-cancer mechanisms of FA-P3-PTX and FA-P7-PTX might be a mitochondrial impairment and caspase-3-dependent apoptotic cell death. Furthermore, the in vivo antitumor efficacy study confirmed that FA-P7-PTX performed more stronger potency in inhibition of tumors growth than PTX. The study demonstrated that conjugate FA-P7-PTX with superior properties for antineoplastic activity, which makes it a promising potential candidate for drug-resistant cancer therapy.
USES OF ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES
-
Paragraph 00347; 00348, (2021/09/03)
Described herein are anti-CD3 antibody folate bioconjugates and uses thereof in the treatment of diseases, conditions, and cancers.
ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES AND THEIR USES
-
Paragraph 00338-00340, (2020/03/23)
Described herein are novel anti-CD3 Folate antibodies and uses thereof in the treatment of diseases or conditions that would benefit from such.